We are live on
!
Find out more
Rockefeller Capital Management Portfolio holdings
AUM
$56.4B
1-Year Est. Return
24.96%
This Fund
S&P 500
This Quarter
Est. Return
-0.57%
1 Year Est. Return
+24.96%
3 Year Est. Return
+83.53%
5 Year Est. Return
+100.91%
10 Year Est. Return
–
AUM
$19B
AUM Growth
+$1.28B
(+7.2%)
Cap. Flow
+$1.55B
Cap. Flow
% of AUM
8.12%
Top 10 Holdings %
Top 10 Hldgs %
20.03%
Holding
3,992
New
448
Increased
1,821
Reduced
816
Closed
180
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elanco Animal Health
ELAN
|
+$89.1M |
| 2 |
WEX
WEX
|
+$78.4M |
| 3 |
Blackrock
BLK
|
+$73.2M |
| 4 |
Vanguard S&P 500 ETF
VOO
|
+$71.9M |
| 5 |
OneMain Financial
OMF
|
+$45.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$63.6M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$56.6M |
| 3 |
Agnico Eagle Mines
AEM
|
+$55.1M |
| 4 |
DFS
Discover Financial Services
DFS
|
+$36M |
| 5 |
ORBC
ORBCOMM, Inc.
ORBC
|
+$27.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.39% |
| 2 | Financials | 14.65% |
| 3 | Healthcare | 12.11% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 6.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BWIN
226
Baldwin Insurance Group
BWIN
$2.77B
| $18.1M | 0.1% |
544,250
-13,205
| -2% | -$413K |
|
227
iShares Select Dividend ETF
DVY
$23.5B
| $18.1M | 0.1% |
157,620
+7,914
| +5% | +$925K |
|
|
XYZ
228
Block Inc
XYZ
$47B
| $17.9M | 0.09% |
74,799
-8,355
| -10% | -$2.15M |
|
229
LyondellBasell Industries
LYB
$19.8B
| $17.9M | 0.09% |
191,086
+19,432
| +11% | +$1.91M |
|
230
Air Products & Chemicals
APD
$66.8B
| $17.5M | 0.09% |
68,188
+21,039
| +45% | +$5.82M |
|
231
iShares Biotechnology ETF
IBB
$9.53B
| $17.3M | 0.09% |
107,080
+4,484
| +4% | +$755K |
|
|
PRO
232
DELISTED
PROS Holdings
PRO
| $17.3M | 0.09% |
487,422
+1,326
| +0.3% | +$55.7K |
|
233
Illinois Tool Works
ITW
$84.8B
| $17.3M | 0.09% |
83,623
+9,469
| +13% | +$2.13M |
|
234
Herc Holdings
HRI
$5.62B
| $17.3M | 0.09% |
105,629
-2,118
| -2% | -$268K |
|
235
Novartis
NVS
$293B
| $17.2M | 0.09% |
210,040
+9,174
| +5% | +$825K |
|
236
Vanguard Short-Term Corporate Bond ETF
VCSH
$44.7B
| $17.1M | 0.09% |
207,536
+14,026
| +7% | +$1.16M |
|
237
iShares MSCI Japan ETF
EWJ
$22.5B
| $17M | 0.09% |
241,552
+20,417
| +9% | +$1.41M |
|
238
Vanguard Morningstar Mid-Cap ETF
VO
$108B
| $16.8M | 0.09% |
283,784
+26,900
| +10% | +$1.63M |
|
239
Utz Brands
UTZ
$2.04B
| $16.6M | 0.09% |
971,215
+431,933
| +80% | +$8.78M |
|
240
Union Pacific
UNP
$175B
| $16.5M | 0.09% |
84,098
+13,012
| +18% | +$2.81M |
|
241
Diageo
DEO
$51.6B
| $16.4M | 0.09% |
85,058
-13,375
| -14% | -$2.59M |
|
242
Inogen
INGN
$176M
| $16.3M | 0.09% |
378,626
+38,162
| +11% | +$2.35M |
|
243
Cardlytics
CDLX
$20.4M
| $16.3M | 0.09% |
19,423
+294
| +2% | +$298K |
|
244
Parker-Hannifin
PH
$135B
| $16.3M | 0.09% |
58,291
+19,416
| +50% | +$5.78M |
|
245
Vanguard Health Care ETF
VHT
$18.4B
| $16.2M | 0.09% |
65,709
+2,039
| +3% | +$523K |
|
246
Crown Castle
CCI
$32.7B
| $16.2M | 0.09% |
93,695
-3,062
| -3% | -$592K |
|
247
iShares US Treasury Bond ETF
GOVT
$43.5B
| $16.1M | 0.08% |
606,236
-48,501
| -7% | -$1.3M |
|
248
KKR & Co
KKR
$92.8B
| $15.9M | 0.08% |
260,945
+20,926
| +9% | +$1.31M |
|
249
Intercontinental Exchange
ICE
$84.1B
| $15.8M | 0.08% |
138,042
-12,023
| -8% | -$1.43M |
|
250
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.51B
| $15.8M | 0.08% |
349,560
+60,823
| +21% | +$2.87M |
|
Similar funds
NAMI
Rockefeller Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Rockefeller Capital Management held 3,992 positions worth $19B, up 7.2% from $17.8B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Rockefeller Capital Management deployed $1.55B of net new capital in Q3 2021, opening 448 new positions and adding to 1,821 existing holdings. Its largest new stake was Darling Ingredients: 56,725 shares worth $4.08M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $63.6M trimmed.
- Rockefeller Capital Management's largest Q3 2021 buy was Darling Ingredients: 56,725 shares worth $4.08M.
- Rockefeller Capital Management added most to Elanco Animal Health in Q3 2021, an estimated $89.1M increase.
- Rockefeller Capital Management's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $63.6M.
- Rockefeller Capital Management fully exited ORBCOMM, Inc. in Q3 2021, selling an estimated $27.5M.
- Rockefeller Capital Management's ten largest holdings make up 20% of its $19B portfolio in Q3 2021.
- Rockefeller Capital Management opened 448 new positions and closed 180 in Q3 2021.
- Rockefeller Capital Management's portfolio value rose 7.2% quarter-over-quarter to $19B.
Based on Rockefeller Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.